An in-depth analysis of our bull call spread position on Replimune (NASDAQ: REPL) ahead of the FDA's PDUFA decision on RP1, including our valuation methodology and trade execution.

Analysis of the FDA's surprising rejection of Replimune's RP1 and the implications for future drug approvals under new leadership.

Interactive options pricing calculator using the Black-Scholes model with real-time Greeks computation for European-style options.

Interactive visualization of historical and projected data center distribution across U.S. states from 2008-2030, powered by machine learning models.

Novana Research examines the data center: its role in the AI value chain, infrastructure context, and future expansion hotbeds.

This piece is a part of Novana Scientific's "Concrete Foundations of Compute" series. Exploring the rise of biological (wetware) computing, its pioneers, and the future of hybrid AI hardware.

Overview of Novasna's beta-neutral short sale of Unicycive (UNCY) ahead of its FDA decision, betting the market had mispriced regulatory risk.

Analysis of tariff-driven cost pressures in the U.S. biotech supply chain, highlighting emerging opportunities in high-margin therapeutics and diagnostics.

We backtest three factor investing-frameworks for U.S. biotech equities against a 15 year period, finding that none produced statistically significant alpha.